Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Insilico Medicine is betting that AI can help design vaccines that slow aging itself. The company's new Longevity Vaccines initiative uses engineered T-cells — guided by circular mRNA and targeted nanoparticles — to eliminate the specific cell populations that kick off age-related diseases. The first target: the aging immune system.
Insilico Medicine, a generative AI drug discovery company, has launched its Longevity Vaccines initiative — a research program designed to use a patient's own immune cells to wipe out the cellular culprits behind age-related disease. Rather than treating symptoms after they appear, the approach aims to eliminate "initiating" cell populations — like senescent cells, pro-fibrotic fibroblasts, and autoreactive lymphocytes — before they trigger downstream damage.
The platform works by delivering a short-lived genetic instruction via circular mRNA (cmRNA) packaged in a targeted lipid nanoparticle (LNP), which arms the body's T-cells to seek and destroy specific harmful cell types. Insilico's end-to-end AI platform, Pharma.AI, handles everything from target discovery to construct design, using aging foundation models to pinpoint the earliest divergent cell states in disease trajectories. The first focus area is immunosenescence — the gradual decline of immune function with age.
By the Numbers:
Why it matters: If successful, longevity vaccines could shift medicine from reactive treatment to proactive prevention of aging-related diseases — potentially reducing the burden of conditions like fibrosis, metabolic dysfunction, and immune decline with a single therapeutic course.
